{"id":2942,"date":"2016-12-15T03:06:41","date_gmt":"2016-12-15T08:06:41","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=2942"},"modified":"2025-09-20T19:17:01","modified_gmt":"2025-09-21T01:17:01","slug":"antibiotic-inhalers-galore-part-1-more-combinations-permutations-rubiks-cube","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2016\/12\/15\/2942\/antibiotic-inhalers-galore-part-1-more-combinations-permutations-rubiks-cube\/","title":{"rendered":"Antibiotic Inhalers Galore (Part 1): \u00a0More Combinations and Permutations than a Rubik\u2019s Cube"},"content":{"rendered":"<p><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-2944\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?resize=530%2C149&#038;ssl=1\" alt=\"\" width=\"530\" height=\"149\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?w=640&amp;ssl=1 640w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?resize=300%2C84&amp;ssl=1 300w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/p>\n<p>There is much interest in inhaled antibiotics these days.\u00a0 Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy plus optimized safety combined.\u00a0 However, some high-profile failures were published recently and should give pause for reflection.<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a><\/p>\n<p>Before analyzing these specific antibiotic trials and their results, let\u2019s start with an overview of the field.\u00a0<div class=\"simplePullQuote right\"><p><span style=\"color: #339966\">Systemic antibiotics must overcome diffusion barriers and penetrate the lung parenchyma to get to\u00a0the infection site, while nebulized antibiotics are right at the air\/tissue interface where bacteria gain entry to the lung<\/span><\/p>\n<\/div><\/p>\n<p>With so many antibiotics in development for pulmonary delivery, it is hard to keep things organized mentally. Dry vs wet inhalers, aqueous vs liposomal delivery systems, different indications and more advanced inhaler technologies are all vying for attention. Indeed, it is hard to see differentiation in this melee even for experts.<\/p>\n<p>For starters, here are the indications \u2013 some old, some new &#8211; pursued by antibiotic aerosol developers:<\/p>\n<ul>\n<li>As adjuvant therapy in CF patients<\/li>\n<li>As prophylaxis for exacerbations of CF<\/li>\n<li>As adjuvant therapy in VAP<\/li>\n<li>As prophylaxis for nosocomial pneumonia in ventilated patients<\/li>\n<li>As treatment of NCFB<\/li>\n<li>As adjuvant therapy in NTM<\/li>\n<\/ul>\n<p>Traditionally, we had CF patients in mind when talking about pulmonary delivery of antibiotics. With Pseudomonas and other difficult-to-treat Gram-negatives becoming established in the lungs of CF patients, efforts to reduce the bacterial burden and possibly reduce the need for systemic antibiotics made good sense. Both Tobi (tobramycin) and Cayston (aztreonam) have potent anti-pseudomonal activity and were approved based on improvement in clinical (FEV1) and microbiologic (CFU) parameters.<\/p>\n<p>Since the days of Tobi and Cayston this field has become a lot more complex. The following antibiotics are studied or used as inhaled agents (and there may be more):<\/p>\n<p><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-2946\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?resize=530%2C433&#038;ssl=1\" alt=\"\" width=\"530\" height=\"433\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?w=1739&amp;ssl=1 1739w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?resize=300%2C245&amp;ssl=1 300w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?resize=768%2C627&amp;ssl=1 768w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?resize=1024%2C836&amp;ssl=1 1024w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Capture.jpg?w=1590&amp;ssl=1 1590w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/p>\n<p>While these antibiotics are of proven efficacy; they are also generics and cheap. But this is an inhaler, not an antibiotic business: Pennies will go into the antibiotic and pounds into the inhaler technology. And big bucks will be charged for the product that makes it to the market.<\/p>\n<p>This is an attractive business model: With drug safety and microbial efficacy already established, it is now a matter of finding respiratory conditions in which symptoms respond to a reduction in\u00a0bacterial load. While CF was the poster boy for this concept, companies are really interested in the much larger VAP and bronchiectasis markets.<\/p>\n<p>A reliable inhaler technology is sine-qua non, of course. Developing an inhaler is tricky business, just ask Bayer about its foray into the field. Their Bayhaler was a beautiful device in its simplicity but unfortunately, it did not work.<\/p>\n<p>Maybe it is surprising that a few antibiotic classes are still missing from the list. Let\u2019s see:<\/p>\n<ul>\n<li>Systemically administered sulfonamides and oxazolidinones have good lung penetration and are safe drugs; hence\u00a0there is no great need for inhaled delivery to avoid systemic toxicity<\/li>\n<li>Noone would consider daptomycin a good choice for aerosol delivery but other similar glycol(lipo)peptides do not get inactivated by surfactant and could be explored.<\/li>\n<li>Doxycycline can be formulated for pulmonary delivery but tetracyclines are pulmonary irritants and doxycycline is cytotoxic for bronchial epithelial cells.<\/li>\n<li>TB drugs could be considered for pulmonary delivery as adjuvant therapy but data are sparse and no drugs are currently being tested for inhalational use.<\/li>\n<\/ul>\n<p>While the\u00a0rationale for antibiotic delivery via the pulmonary route is solid, supporting evidence-based data are sparse or non-existent. Nonetheless, intensivists often use antibiotic aerosols already as empirical adjunctive therapy in ventilated ICU patients; experts have spoken out in favor\u00a0<a href=\"#_ftn6\" name=\"_ftnref6\">[6]<\/a>\u00a0and against the practice\u00a0<a href=\"#_ftn6\" name=\"_ftnref6\">[7]<\/a>.<\/p>\n<div class=\"simplePullQuote right\"><p><span style=\"color: #800000\">Areas of atelectasis and segments with pneumonic consolidation are cut off from ventilation and cannot be reached by nebulized medicines<\/span><\/p>\n<\/div>\n<p>With this as a primer, we can discuss recent trial results from Aradigm \u2013 Bayer \u2013 Cardeas &#8211; Insmed in an upcoming blog. Be forewarned: it\u2019s a scary world out there!<\/p>\n<p><strong>Abbreviations<br \/>\n<\/strong>CF\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 cystic fibrosis<br \/>\nCFU\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 colony-forming units<br \/>\nDPI\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 dry powder inhaler<br \/>\nFEV1\u00a0\u00a0\u00a0\u00a0 forced expiratory volume (first second)<br \/>\nNTM \u00a0 \u00a0 \u00a0 non-tuberculous mycobacteria<br \/>\nNCFB\u00a0\u00a0\u00a0\u00a0 non-CF-bronchiectasis<\/p>\n<p><strong>Publications:<br \/>\n<\/strong><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Kollef M.\u00a0 A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia:- IASIS Trial, CHEST (2016), doi: 10.1016\/j.chest.2016.11.026<br \/>\n<a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> http:\/\/www.icid.salisbury.nhs.uk\/ClinicalManagement\/Respiratory\/Pages\/NebulisedAntibioticDrug-Gentamicin.aspx<br \/>\n<a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> Antoniu S: Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opin Pharmacother. 2011;12:1191<br \/>\n<a href=\"#_ftnref4\" name=\"_ftn4\">[4]<\/a> Approved in the EU<br \/>\n<a href=\"#_ftnref5\" name=\"_ftn5\">[5]<\/a> Zhang Y High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm. 2010 Aug 16;395:205<br \/>\n<a href=\"#_ftnref6\" name=\"_ftn6\">[6]<\/a> Wunderink RG, Point: Should inhaled antibiotic therapy be routinely used for the treatment of bacterial lower respiratory tract infections in the ICU setting? Yes, CHEST (2016), doi: 10.1016\/j.chest.2016.11.006.<br \/>\n<a href=\"#_ftnref6\" name=\"_ftn6\">[7]<\/a>\u00a0\u00a0Kollef MH, Counterpoint: Should inhaled antibiotic therapy be routinely used<br \/>\nfor the treatment of bacterial lower respiratory tract infections in the ICU setting? No, CHEST (2016), doi:\u00a010.1016\/j.chest.2016.11.007<\/p>\n","protected":false},"excerpt":{"rendered":"<p>There is much interest in inhaled antibiotics these days.\u00a0 Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy plus optimized safety combined.\u00a0 However, some high-profile failures were published <a class=\"more-link\" href=\"https:\/\/allphasepharma.com\/dir\/2016\/12\/15\/2942\/antibiotic-inhalers-galore-part-1-more-combinations-permutations-rubiks-cube\/\">Continue reading <span class=\"screen-reader-text\">  Antibiotic Inhalers Galore (Part 1): \u00a0More Combinations and Permutations than a Rubik\u2019s Cube<\/span><span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":2944,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[19,227,3,18],"tags":[1841,1866,893,1271,1112,1849,403,594,897,650,211,336,220,1838,892,596,885,347,1844,42,177,905,1839,891,85,228,427,898,766,126,1583,1850,1836,627,889,1845,598,213,1353,346,747,83,1843,1842,1847,1848,174,1472,1852,895,196,1840,1371,1846,1812,73,263,1851,886,1837,887,356,48,79],"class_list":["post-2942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qidp_antibiotic","category-recent_literature","category-the_news","category-the_viewpoint","tag-aeroquin","tag-aerosolized-antibiotics","tag-aerovanc","tag-allphase-pharma-consulting","tag-amikacin","tag-amphotericin","tag-antibiotic-blog","tag-aradigm","tag-arikayce","tag-aspergillus","tag-azithromycin","tag-aztreonam","tag-bayer","tag-bayhaler","tag-bronchiectasis","tag-cardeas","tag-cayston","tag-ceftazidime","tag-cf","tag-ciprofloxacin","tag-colistin","tag-colobreathe","tag-curx","tag-cystic-fibrosis","tag-dalvance","tag-daptomycin","tag-doxycycline","tag-fosfomycin","tag-gentamicin","tag-gilead","tag-harald-reinhart","tag-horizon","tag-iasis","tag-imipenem","tag-inhaled-antibiotics","tag-inhaler-business","tag-insmed","tag-levofloxacin","tag-meiji","tag-meropenem","tag-merrem","tag-mrsa","tag-ncfb","tag-ncfbe","tag-nebulized-antibiotics","tag-nebupent","tag-novartis","tag-ntm","tag-pcp-prophylaxis","tag-pentamidine","tag-pseudomonas","tag-pulmaquin","tag-qidp","tag-quinsair","tag-savara","tag-surfactant","tag-tetracycline","tag-teva","tag-tobi","tag-tobi-podhaler","tag-tobramycin","tag-vabp","tag-vancomycin","tag-vap"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/12\/Inhalational-Abx-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-Ls","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1314,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/25\/1314\/aerosolized-antibiotics-selling-nebulizers\/","url_meta":{"origin":2942,"position":0},"title":"Aerosolized Antibiotics &#038; Selling Nebulizers","author":"Harald","date":"March 25, 2015","format":false,"excerpt":"\u201cThe medicine comes for free, just pay us for the inhaler\u201d should be the marketing slogan for this group of therapeutics.\u00a0 Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to \u2018evergreen\u2019 off-patent antibiotics. The inhalational route to administer antibiotics is clearly attractive.\u00a0\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":1332,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/28\/1332\/drugs-with-qidp-designation-update-3282015\/","url_meta":{"origin":2942,"position":1},"title":"Drugs with QIDP Designation \u2013 Update 4\/8\/2015","author":"Harald","date":"March 28, 2015","format":false,"excerpt":"For the latest QIDP listing, please click HERE Our latest internet search came up with 37 drugs that garnered QIDP status.\u00a0 They are listed in the Table below (if I missed a compound, please leave a comment!!). \u00a0The\u00a0table is searchable so you should be able to massage the data to\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"APPC + QIDP copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/10\/APPC-QIDP-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2817,"url":"https:\/\/allphasepharma.com\/dir\/2016\/10\/24\/2817\/qidp-drug-update-part-2-categories-of-interest\/","url_meta":{"origin":2942,"position":2},"title":"QIDP Drug Update \u2013 Part 2: \u00a0Categories of Interest","author":"Harald","date":"October 24, 2016","format":false,"excerpt":"According to Janet Woodcock, 63 drugs have been given the \u201cQIDP\u201d designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development.\u00a0 So we are in fairly close agreement. That may seem like an impressive record but it is also\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"qidp-part2-slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2911,"url":"https:\/\/allphasepharma.com\/dir\/2016\/11\/25\/2911\/prospecting-antibiotics\/","url_meta":{"origin":2942,"position":3},"title":"Prospecting for New Antibiotics","author":"Harald","date":"November 25, 2016","format":false,"excerpt":"The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA\u00a0expedited review and more.\u00a0 In addition, FDA made it quite easy to garner the label.\u00a0 As you can see, there is really no downside to\u2026","rel":"","context":"In &quot;Did you know...?&quot;","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"engine-qidp-blog","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":157,"url":"https:\/\/allphasepharma.com\/dir\/2014\/04\/22\/157\/antibiotics-with-qidp-designation\/","url_meta":{"origin":2942,"position":4},"title":"Antibiotics with QIDP Designation &#8211;   &#8211;    &#8211;  Updated 9-30-14","author":"Harald","date":"April 22, 2014","format":false,"excerpt":"For the latest QIDP listing, please click HERE \u00a0 Since\u00a0FDA issued the QIDP designation in 2012, many companies have requested this important 'label'. \u00a0Which should not come as a surprise: QIDP status confers significant benefits - and there is no downside. While an official FDA list of drugs that have\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/04\/FDA-GAIN-LPAD-banner-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/04\/FDA-GAIN-LPAD-banner-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/04\/FDA-GAIN-LPAD-banner-copy.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":2205,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/23\/2205\/qidp-antibiotics-2015-year-end-update\/","url_meta":{"origin":2942,"position":5},"title":"QIDP Antibiotics  &#8211;  2015 Year-End Update","author":"Harald","date":"December 23, 2015","format":false,"excerpt":"Here an updated listing of all QIDP drugs we are aware of as of 12\/24\/2015. Today just\u00a0facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are\u00a058 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=2942"}],"version-history":[{"count":9,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2942\/revisions"}],"predecessor-version":[{"id":2953,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2942\/revisions\/2953"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/2944"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=2942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=2942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=2942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}